MorphoSys posts positive data for lymphoma drug, but will it compete with CAR-Ts?
A spokesperson for the company noted that patients in the Phase II L-MIND trial of the CD19-targeting drug tafasitamab would be too old and frail to be candidates for CAR-T therapies.